

**FOR IMMEDIATE RELEASE**

Contact: Mark N. Schwartz, CEO  
(651) 687-9999

## **Hypertension Diagnostics Announces FY 2009 Second Quarter Results**

ST. PAUL, MN – February 13, 2009 – Hypertension Diagnostics, Inc. (OTC: HDII.OB), today announced financial results for the second quarter (Q2) of fiscal year 2009 ended December 31, 2008.

Revenue for Q2 2009 totaled \$137,207 compared to \$145,662 for Q2 2008 ending December 31, 2007, which represents a 5.8% decrease. The Company's net loss was \$191,165 for Q2 2009 or \$.00 per share, compared with a net income of \$165,448 for Q2 2008, or \$.00 per share. Included in the net loss for Q2 2009 are total non-cash charges (mainly deferred compensation, depreciation, stock options) of \$92,178. In Q2 2008, total non-cash benefits were \$252,870. The decline in the Company's stock price during Q2 2008 resulted in a negative expense for the Q2 2008 deferred compensation expense of \$283,500. This caused the company to report net income, which would not have occurred without the negative deferred compensation expense in Q2 2008. The Company reported a cash balance on December 31, 2008 of \$914,741.

For the six month period ended December 31, 2008, total revenue was \$273,719, compared to \$292,014 for the six month period ended December 31, 2007, a 6.3% decrease. For the six month period ended December 31, 2008, the Company incurred a net loss of \$69,560, including a non-cash benefit of \$111,854, or \$.00 per share, compared with a net loss of \$290,760, including a non-cash charge of \$64,106, or \$(.01) per share, for the six month period ended December 31, 2007.

"While the current quarter shows a decline in revenues from the comparable quarter in the last fiscal year, we are excited by the opportunity in the international markets, where prevention of cardiovascular disease is becoming standard of care," said Mark Schwartz, Chairman and CEO. "The Company has been working with new international distributors in the European and Asian markets to compete in the emerging vascular screening market where we believe our products have a compelling clinical advantage over our competitors."

Forward-looking statements in this press release are made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The Company wishes to caution readers not to place undue reliance on any forward-looking statements and to recognize that the statements are not a prediction of actual future results. Actual results could differ materially from those presented and anticipated in the forward-looking statements due to the risks and uncertainties set forth in the Company's 2008 Annual Report on Form 10-KSB, and subsequent Quarterly Reports on Form 10-Q, all of which were filed with the U.S. Securities and Exchange Commission, as well as others not now anticipated.

**Hypertension Diagnostics, Inc.**  
**Summary Financial Data**

**Statements of Operations**

	Three Months Ended December 31		Six Months Ended December 31	
	2008	2007	2008	2007
Revenue:				
Equipment sales	\$ 96,837	\$ 91,705	\$ 178,837	\$ 183,635
Equipment rental	24,119	35,558	49,816	81,785
Service/contract income	16,251	18,399	45,066	26,594
	<u>137,207</u>	<u>145,662</u>	<u>273,719</u>	<u>292,014</u>
Cost of Sales	2,976	12,113	7,507	14,441
Gross Profit	<u>134,231</u>	<u>133,549</u>	<u>266,212</u>	<u>277,573</u>
Selling, general & administrative expenses	328,759	(17,963)	345,619	597,022
Total Expense	<u>328,759</u>	<u>(17,963)</u>	<u>345,619</u>	<u>597,022</u>
Operating Income (Loss)	<u>(194,528)</u>	<u>151,512</u>	<u>(79,407)</u>	<u>(319,449)</u>
Interest income	3,363	13,936	9,847	28,689
Net Income (Loss)	<u>\$ (191,165)</u>	<u>\$ 165,448</u>	<u>\$ (69,560)</u>	<u>\$ (290,760)</u>
Basic and Diluted Net Loss per Share	\$ .00	\$ .00	\$ .00	\$ (.01)
Basic and Diluted Weighted Average Shares Outstanding	40,795,820	39,666,835	40,579,411	39,658,077

**Balance Sheet Data**

	December 31, 2008	June 30, 2008
Cash and cash equivalents	\$ 914,741	\$ 1,081,868
Total current assets	1,201,440	1,408,379
Total assets	1,215,702	1,427,786
Total current liabilities	394,157	585,280
Accumulated deficit	(27,255,727)	(27,186,167)
Total shareholders' equity	793,171	816,981

# # #

CVProfilor is a registered trademark of Hypertension Diagnostics, Inc.  
Hypertension Diagnostics, HDI/PulseWave, PulseWave and CVProfile are trademarks of  
Hypertension Diagnostics, Inc. All rights reserved.  
Website: [www.hdii.com](http://www.hdii.com)